Samphire
Brain-based period pain and mood relief
London, UK
Samphire is developing the Nettle™ device for chronic menstrual conditions. The company was founded in 2021, has raised $7.3M in pre-seed and seed funding, and achieved CE certification for UK and EU markets.
How We Help
Problem Statement
Chronic menstrual conditions affecting approximately 190 million people globally.
Core Technology
Nettle™ device
Key Differentiators
CE-certified medical device for UK and EU markets; Backed by decades of research
Clinical Focus
menstrual symptoms
Company Info
- Business Model
- Device Sales
- Founded
- 2021
- Total Funding
- 7,300,000
- Website
- samphireneuro.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Double-blind WIND 2024 trial: 72% pain reduction, 67% mood improvement, 100% PMDD symptom improvement in severe cases; Class IIa medical device (EU/UK)
MedStartr Index Score
?What do you think of Samphire?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.